Research ArticleOriginal Research

Factors That Influence Treatment Completion for Latent Tuberculosis Infection

McKenna C. Eastment, Adelaide H. McClintock, Christy M. McKinney, Masahiro Narita and Alexandra Molnar
The Journal of the American Board of Family Medicine July 2017, 30 (4) 520-527; DOI: https://doi.org/10.3122/jabfm.2017.04.170070

References

  1. 1.↵
    1. Bennett DE,
    2. Courval JM,
    3. Onorato I,
    4. et al
    . Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999–2000. Am J Respir Crit Care Med 2008;177:348–55.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Ferebee SH
    . Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28–106.
    OpenUrlPubMed
  3. 3.↵
    1. Smieja MJ,
    2. Marchetti CA,
    3. Cook DJ,
    4. Smaill FM
    . Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;(2):CD001363.
  4. 4.↵
    1. Churchyard GJ,
    2. Fielding KL,
    3. Lewis JJ,
    4. et al
    . A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370:301–10.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Porco TC,
    2. Lewis B,
    3. Marseille E,
    4. Grinsdale J,
    5. Flood JM,
    6. Royce SE
    . Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006;6:157.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Holland DP,
    2. Sanders GD,
    3. Hamilton CD,
    4. Stout JE
    . Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009;179:1055–60.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Goswami ND,
    2. Gadkowski LB,
    3. Piedrahita C,
    4. et al
    . Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health 2012;12:468.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hess K,
    2. Goad J,
    3. Wu J,
    4. Johnson K
    . Isoniazid completion rates for latent tuberculosis infection among college students managed by a community pharmacist. J Am Coll Health 2009;57:553–5.
    OpenUrlPubMed
  9. 9.↵
    1. Rivest P,
    2. Street MC,
    3. Allard R
    . Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010. Can J Public Health 2013;104:e235–9.
    OpenUrl
  10. 10.↵
    Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49(RR-6):1–51.
    OpenUrlPubMed
  11. 11.↵
    Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650–3.
    OpenUrlPubMed
  12. 12.↵
    1. Sharma SK,
    2. Sharma A,
    3. Kadhiravan T,
    4. Tharyan P
    . Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;(7):CD007545.
  13. 13.↵
    1. Hirsch-Moverman Y,
    2. Bethel J,
    3. Colson PW,
    4. Franks J,
    5. El-Sadr W
    . Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis 2010;14:1104–11.
    OpenUrlPubMed
  14. 14.↵
    1. McClintock AH,
    2. Eastment M,
    3. McKinney CM,
    4. et al
    . Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. BMC Infect Dis 2017;17:146.
    OpenUrl
  15. 15.↵
    1. Machado A Jr.,
    2. Finkmoore B,
    3. Emodi K,
    4. et al
    . Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador. Brazil. Int J Tuberc Lung Dis 2009;13:719–25.
    OpenUrlPubMed
  16. 16.↵
    1. Shieh FK,
    2. Snyder G,
    3. Horsburgh CR,
    4. Bernardo J,
    5. Murphy C,
    6. Saukkonen JJ
    . Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006;174:717–21.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Wyss LL,
    2. Alderman MK
    . Using theory to interpret beliefs in migrants diagnosed with latent TB. Online J Issues Nurs 2007;12:7.
    OpenUrlPubMed
  18. 18.↵
    1. West EL,
    2. Gadkowski LB,
    3. Ostbye T,
    4. Piedrahita C,
    5. Stout JE
    . Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. N C Med J 2008;69:14–20.
    OpenUrlPubMed
  19. 19.↵
    1. McEwen MM,
    2. Boyle J
    . Resistance, health, and latent tuberculosis infection: Mexican immigrants at the U. S.-Mexico border. Res Theory Nurs Pract 2007;21:185–97.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Hirsch-Moverman Y,
    2. Shrestha-Kuwahara R,
    3. Bethel J,
    4. et al
    . Latent tuberculous infection in the United States and Canada: who completes treatment and why?. Int J Tuberc Lung Dis 2015;19:31–8.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Nyamathi AM,
    2. Christiani A,
    3. Nahid P,
    4. Gregerson P,
    5. Leake B
    . A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 2006;10:775–82.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    1. Ailinger RL,
    2. Black P,
    3. Nguyen N,
    4. Lasus H
    . Predictors of adherence to latent tuberculosis infection therapy in Latino immigrants. J Community Health Nurs 2007;24:191–8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Harris PA,
    2. Taylor R,
    3. Thielke R,
    4. Payne J,
    5. Gonzalez N,
    6. Conde JG
    . Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    US Code, Title 42, The Public Health and Welfare, 2000, 254b.
  25. 25.↵
    1. Kwara A,
    2. Herold JS,
    3. Machan JT,
    4. Carter EJ
    . Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008;133:862–8.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Gupta V,
    2. Sugg N,
    3. Butners M,
    4. Allen-White G,
    5. Molner A
    . Tuberculosis among the homeless–preventing another outbreak through community action. N Engl J Med 2015;372:1483–5.
    OpenUrl
  27. 27.↵
    1. Jackson-Carroll L,
    2. Graham E,
    3. Jackson JC
    . Beyond medical interpretation: the role of interpreter cultural mediators (ICMs) in building bridges between ethnic communities and health institutions. Selecting, training and supporting key outreach staff. EthnoMed [Internet]Seattle: Harborview Medical Center; 1995 (revised 1998). Available from: http://ethnomed.org/about/related-programs/community-house-calls-program/icm-manual98.pdf.
  28. 28.↵
    1. Ailinger RL,
    2. Martyn D,
    3. Lasus H,
    4. Lima Garcia N
    . The effect of a cultural intervention on adherence to latent tuberculosis infection therapy in Latino immigrants. Public Health Nurs 2010;27:115–20.
    OpenUrlPubMed
  29. 29.↵
    1. Chang AH,
    2. Polesky A,
    3. Bhatia G
    . House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. BMC Public Health 2013;13:894.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords